A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
SKYLINE-UC
Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
1 other identifier
interventional
645
33 countries
222
Brief Summary
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started May 2025
Typical duration for phase_2
222 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 27, 2025
CompletedStudy Start
First participant enrolled
May 27, 2025
CompletedFirst Posted
Study publicly available on registry
June 10, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2028
ExpectedJune 8, 2026
June 1, 2026
1 year
May 27, 2025
June 4, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Part A: Change in Robarts Histopathology Index (RHI)
Change in Robarts Histopathology Index (RHI) from baseline at Week 12 will be assessed. The RHI is used to quantify and assess histological activity of UC, comprising of scores for inflammatory infiltrates, neutrophils, erosions or ulceration. Scores are assigned to each of these features, with a total ranging from 0 (no disease activity) to 33 (most severe disease activity). Higher score indicates more severe disease.
Week 12
Part B: Percentage of participants with clinical remission
Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is based on the modified Mayo subscores, which consist of a rectal bleeding subscore (ranging from 0 to 3), stool frequency subscore (ranging from 0 to 3), and endoscopic subscore (ranging from 0 to 3), as assessed by central reading. Higher scores indicate more severe disease.
Week 12
Secondary Outcomes (7)
Part A: Percentage of participants with clinical remission
Week 12
Part A: Percentage of participants with endoscopic improvement
Week 12
Part B: Percentage of participants with endoscopic improvement
Week 12
Part B: Percentage of participants with clinical response
Week 12
Part B: Percentage of participants with histologic improvement
Week 12
- +2 more secondary outcomes
Study Arms (13)
Intervention Specific Appendix - SPY001: Part A
EXPERIMENTALParticipants will receive open-label dose of SPY001
Intervention Specific Appendix - SPY002: Part A
EXPERIMENTALParticipants will receive open-label dose of SPY002
Intervention Specific Appendix - SPY003: Part A
EXPERIMENTALParticipants will receive open-label dose of SPY003
Intervention Specific Appendix - SPY001 Dosing Regimen 1: Part B
EXPERIMENTALParticipants will receive double-blind dosing regimen 1 of SPY001
Intervention Specific Appendix - SPY001 Dosing Regimen 2: Part B
EXPERIMENTALParticipants will receive double-blind dosing regimen 2 of SPY001
Intervention Specific Appendix - SPY002 Dosing Regimen 1: Part B
EXPERIMENTALParticipants will receive double-blind dosing regimen 1 of SPY002
Intervention Specific Appendix - SPY002 Dosing Regimen 2: Part B
EXPERIMENTALParticipants will receive double-blind dosing regimen 2 of SPY002
Intervention Specific Appendix - SPY003 Dosing Regimen 1: Part B
EXPERIMENTALParticipants will receive double-blind dosing regimen 1 of SPY003
Intervention Specific Appendix - SPY003 Dosing Regimen 2: Part B
EXPERIMENTALParticipants will receive double-blind dosing regimen 2 of SPY003
Intervention Specific Appendix - SPY120: Part B
EXPERIMENTALParticipants will receive double-blind dose of SPY001 and SPY002
Intervention Specific Appendix - SPY130: Part B
EXPERIMENTALParticipants will receive double-blind dose of SPY001 and SPY003
Intervention Specific Appendix - SPY230: Part B
EXPERIMENTALParticipants will receive double-blind dose of SPY002 and SPY003
Placebo: Part B
PLACEBO COMPARATORParticipants will receive matching placebo
Interventions
Experimental
Experimental
Experimental
Eligibility Criteria
You may qualify if:
- Diagnosis of UC for ≥3 months before Day 1, confirmed by endoscopy and histology either previously or during Screening
- Active UC with disease extent of ≥15 cm from the anal verge, as confirmed by Screening endoscopy (up to approximately 15% allowed to have only proctitis)
- Moderately to severely active disease as defined by a modified Mayo score of 5-9, rectal bleeding subscore of ≥1, and Mayo endoscopic subscore ≥2
You may not qualify if:
- Current diagnosis of Crohn's disease or Inflammatory Bowel Disease (IBD)-Undefined
- Confirmed or suspected fulminant colitis, toxic megacolon, bowel perforation and/or other conditions that will likely require surgery during induction
- Failed 4 or more approved or investigational advanced therapy classes
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (223)
Site 024
Canoga Park, California, 91304, United States
Site 023
La Jolla, California, 92037, United States
Site 012
Lancaster, California, 93534, United States
Site 033
Colorado Springs, Colorado, 91304, United States
Site 007
Kissimmee, Florida, 34741, United States
029
Miami, Florida, 33165, United States
Site 006
Kansas City, Kansas, 66160, United States
Site 030
Louisville, Kentucky, 40202, United States
Site 035
Marrero, Louisiana, 70072, United States
Site 011
Glen Burnie, Maryland, 21061, United States
Site 003
Boston, Massachusetts, 02114, United States
Site 028
Rochester, Minnesota, 55905, United States
Site 037
New York, New York, 10065, United States
040
Chapel Hill, North Carolina, 27599, United States
Site 041
Durham, North Carolina, 27710, United States
Site 016
Winston-Salem, North Carolina, 27103, United States
Site 025
Providence, Rhode Island, 02904, United States
Site 017
Kingsport, Tennessee, 37663, United States
Site 013
Cedar Park, Texas, 78613, United States
Site 005
Garland, Texas, 75246, United States
Site 002
San Antonio, Texas, 78229, United States
Site 008
Southlake, Texas, 76092, United States
Site 009
Webster, Texas, 77598, United States
Site 004
Seattle, Washington, 98195, United States
Site 019
Tacoma, Washington, 98405, United States
Site 103
Rosario, Sant Fe, 2000, Argentina
Site 104
San Miguel de Tucumán, Tucumán Province, 4000, Argentina
Site 208
Concord, 2139, Australia
Site 202
Heidelberg, 3084, Australia
Site 204
Liverpool, 2170, Australia
Site 203
Melbourne, 3004, Australia
Site 206
South Brisbane, 4101, Australia
Site 207
Woolloongabba, 4102, Australia
Site 463
Linz, 4021, Austria
Site 476
Ghent, Osst-Vlaanderen, 9000, Belgium
Site 474
Sint-Niklaas, Osst-Vlaanderen, 9100, Belgium
Site 475
Bruges, 8310, Belgium
Site 471
Ghent, 9000, Belgium
Site 472
Roeselare, 9000, Belgium
Site 481
Banja Luka, 78 000, Bosnia and Herzegovina
Site 484
Mostar, 88000, Bosnia and Herzegovina
Site 483
Sarajevo, 71000, Bosnia and Herzegovina
Site 494
Gorna Oryahovitsa, 5100, Bulgaria
Site 498
Rousse, 7002, Bulgaria
Site 492
Sofia, 1343, Bulgaria
Site 495
Sofia, 1463, Bulgaria
Site 083
London, Ontario, G8H 3P7, Canada
Site 085
Greater Sudbury, P3C1X3, Canada
Site 086
London, N6K 1M6, Canada
Site 153
Osorno, Los Lagos Region, 5290000, Chile
Site 521
Osijek, 31000, Croatia
Site 531
Brno, 615 00, Czechia
Site 536
Klatovy, 33901, Czechia
Site 534
Ostrava, 702 00, Czechia
Site 537
Pardubice, 532 03, Czechia
Site 538
Prague, 150 00, Czechia
Site 555
Marseille, 13015, France
Site 551
Nantes, 44300, France
Site 557
Nice, 06200, France
Site 556
Pierre-Bénite, 69310, France
Site 558
Saint-Etienne, 42270, France
Site 584
Kutaisi, 4600, Georgia
Site 589
Marneuli, 3000, Georgia
Site 581
Tbilisi, 0102, Georgia
Site 588
Tbilisi, 0114, Georgia
Site 583
Tbilisi, 01444, Georgia
Site 586
Tbilisi, 0144, Georgia
Site 582
Tbilisi, 0159, Georgia
Site 587
Tbilisi, 0159, Georgia
Site 590
Tbilisi, 0178, Georgia
Site 585
Tbilisi, 0180, Georgia
Site 606
Berlin, 10117, Germany
Site 604
Berlin, 14163, Germany
Site 611
Brandenburg an der Havel, 14770, Germany
Site 607
Dachau, 85221, Germany
Site 610
Frankfurt am Main, 60590, Germany
Site 602
Kiel, 24105, Germany
Site 608
Leipzig, 04103, Germany
Site 609
Munich, 81377, Germany
Site 603
Ulm, 89081, Germany
Site 635
Athens, Attica, 11527, Greece
Site 634
Athens, 10676, Greece
Site 632
Athens, 115 27, Greece
Site 631
Chaïdári, 124 62, Greece
Site 654
Békéscsaba, H-5600, Hungary
Site 655
Budapest, H-1062, Hungary
Site 656
Budapest, H-1083, Hungary
Site 651
Budapest, H-1088, Hungary
Site 652
Székesfehérvár, H-8000, Hungary
Site 270
Hyderabad, 500032, India
Site 268
Jaipur, 302004, India
Site 266
Kochi, 682040, India
Site 265
Sūrat, 395002, India
Site 445
Beer Yaaqov, 7033001, Israel
Site 441
Beersheba, 8410101, Israel
Site 443
Haifa, 31048, Israel
Site 444
Jerusalem, 9103102, Israel
Site 446
Jerusalem, 9112001, Israel
Site 442
Nahariya, 2210001, Israel
Site 682
Castellana Grotte, Bari, 70013, Italy
Site 679
Pavia, Lombardy, 27100, Italy
Site 673
Legnano, Milan, 20025, Italy
Site 674
Rozzano, Milan, 20089, Italy
Site 676
San Donato Milanese, Milan, 20097, Italy
Site 671
Segrate, Milan, 20132, Italy
Site 680
Turin, Piedmont, 10126, Italy
Site 683
Bologna, 40138, Italy
Site 672
Negrar, 37024, Italy
Site 677
Padova, 35128, Italy
Site 681
Rome, 00168, Italy
Site 675
Turin, 10128, Italy
Site 299
Kashiwa, Chiba, 277-0871, Japan
Site 294
Chikushino-shi, Fukuoka, 818-8502, Japan
Site 292
Shiwa-gun, Iwate, 028-3695, Japan
Site 290
Ōita, Oita Prefecture, 870-0823, Japan
Site 282
Chuo Ku, Osaka, 540-0006, Japan
Site 291
Kobe, 650-0015, Japan
Site 286
Saga, 849-8501, Japan
Site 285
Sendai, 981-3213, Japan
Site 293
Urayasu-shi, 279-0021, Japan
Site 425
Amman, 11194, Jordan
Site 424
Amman, 11196, Jordan
Site 421
Amman, 11942, Jordan
Site 422
Irbid, 21110, Jordan
Site 423
Irbid, 22110, Jordan
Site 426
Irbid, 22110, Jordan
Site 704
Klaipėda, LT-92288, Lithuania
Site 703
Vilnius, LT-08406, Lithuania
Site 174
Saltillo, Coahuila, 25050, Mexico
Site 175
Celaya, Guanajuato, 38000, Mexico
Site 173
Tlajomulco de Zúñiga, Jalisco, 45645, Mexico
Site 713
Chisinau, MD2005, Moldova
Site 711
Chisinau, MD2025, Moldova
Site 712
Chisinau, MD2025, Moldova
Site 714
Chisinau, MD2025, Moldova
Site 715
Chisinau, MD2068, Moldova
Site 753
Bydgoszcz, 85-2299, Poland
Site 732
Bydgoszcz, 85-794, Poland
Site 749
Katowice, 40-600, Poland
Site 735
Katowice, 40-748, Poland
Site 748
Krakow, 31-501, Poland
Site 743
Opole, 45-819, Poland
Site 740
Poznan, 60-309, Poland
Site 736
Rzeszów, 35-326, Poland
Site 744
Sopot, 81-756, Poland
Site 745
Staszów, 28-2200, Poland
Site 737
Szczecin, 71-434, Poland
Site 733
Szczecin, 71-685, Poland
Site 752
Tychy, 43-100, Poland
Site 739
Warsaw, 00--710, Poland
Site 751
Warsaw, 00-189, Poland
Site 754
Warsaw, 02-172, Poland
Site 741
Warsaw, 02-786, Poland
Site 731
Warsaw, 04-501, Poland
Site 750
Warsaw, 57-300, Poland
Site 738
Wroclaw, 52-416, Poland
Site 734
Wroclaw, 53-149, Poland
Site 747
Wroclaw, 53-611, Poland
Site 742
Wroclaw, 54-239, Poland
Site 783
Bucharest, 011273, Romania
Site 784
Bucharest, 014142, Romania
Site 781
Bucharest, 020125, Romania
Site 782
Cluj-Napoca, 400061, Romania
Site 786
Constanța, 900161, Romania
Site 788
Timișoara, 300239, Romania
Trial Site 804
Belgrade, 11 000, Serbia
Site 802
Belgrade, 11000, Serbia
Site 807
Belgrade, 11000, Serbia
Site 803
Belgrade, 11080, Serbia
Site 805
Niš, 18 000, Serbia
Site 806
Užice, 31000, Serbia
Site 801
Zrenjanin, 23000, Serbia
Site 823
Bratislava, 811 09, Slovakia
Site 822
Košice, 040 13, Slovakia
Site 821
Prešov, 080 01, Slovakia
Site 825
Zvolen, 960 01, Slovakia
Site 357
Busan, 48108, South Korea
Site 354
Daegu, 40404, South Korea
Site 358
Daegu, 42415, South Korea
Site 361
Daegu, 42601, South Korea
Site 355
Daejeon, 34943, South Korea
Site 356
Seoul, 03312, South Korea
Site 351
Seoul, 03722, South Korea
Site 352
Seoul, 06591, South Korea
Site 360
Seoul, 07985, South Korea
Site 362
Seoul, 6351, South Korea
Site 359
Suwon, 16247, South Korea
Site 353
Wŏnju, 26426, South Korea
Site 832
Santiago de Compostela, A Coruna, 15702, Spain
Site 835
Gijón, 33394, Spain
Site 838
Lugo, 27003, Spain
Site 834
Madrid, 28031, Spain
Site 837
Madrid, 28222, Spain
Site 836
Ourense, 32005, Spain
Site 831
Seville, 41013, Spain
Site 852
Basel, 4031, Switzerland
Site 853
Bern, 3012, Switzerland
Site 851
Sankt Gallen, 9007, Switzerland
Site 394
Changhua, 500, Taiwan
Site 392
Chiayi City, 600, Taiwan
Site 395
Kaohsiung City, 833401, Taiwan
Site 396
Taichung, 404327, Taiwan
Site 391
Taipei, 100225, Taiwan
Site 397
Taipei, 104, Taiwan
Site 393
Taoyuan City, 333, Taiwan
Site 866
Kocaeli, 41380, Turkey (Türkiye)
Site 861
Mersin, 33110, Turkey (Türkiye)
Site 865
Sanliurfa, 63290, Turkey (Türkiye)
Site 862
Trabzon, 61080, Turkey (Türkiye)
Site 906
Ivano-Frankivsk, 76008, Ukraine
Site 902
Kyiv, 02002, Ukraine
Site 904
Kyiv, 02091, Ukraine
Site 905
Kyiv, 03037, Ukraine
Site 913
Kyiv, 04050, Ukraine
Site 911
Kyiv, 04107, Ukraine
Site 903
Kyiv, 04210, Ukraine
Site 901
Lutsk, 43005, Ukraine
Site 909
Lviv, 79010, Ukraine
Site 912
Lviv, 79059, Ukraine
Site 914
Poltava, 36011, Ukraine
Site 908
Vinnytsia, 21009, Ukraine
Site 910
Vinnytsia, 21028, Ukraine
Site 907
Vinnytsia, 21029, Ukraine
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
SKYLINE-UC Study Director
Spyre Therapeutics
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 27, 2025
First Posted
June 10, 2025
Study Start
May 27, 2025
Primary Completion
June 1, 2026
Study Completion (Estimated)
March 1, 2028
Last Updated
June 8, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share